Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study

Gilead (GILD) announced positive Phase III trial results for Trodelvy in combination with Merck's (MRK) Keytruda, demonstrating a 35% reduction in the risk of disease progression or death in first-line PD-L1+ metastatic triple-negative breast cancer (TNBC) compared to Keytruda plus chemotherapy; the ASCENT-04/KEYNOTE-D19 study showed a median progression-free survival of 11.2 months versus 7.8 months. Gilead views these results, along with data from the ASCENT-03 study, as evidence that Trodelvy could become a backbone therapy across first-line metastatic TNBC, potentially strengthening its oncology business in the face of headwinds for its Cell Therapy franchise.

Analysis

Gilead Sciences (GILD) has announced compelling positive data from its late-stage ASCENT-04/KEYNOTE-D19 study for Trodelvy in combination with Merck's Keytruda. The trial demonstrated a significant 35% reduction in the risk of disease progression or death for first-line PD-L1+ metastatic triple-negative breast cancer (TNBC) patients when compared to Keytruda plus chemotherapy. This combination achieved a median progression-free survival (PFS) of 11.2 months versus 7.8 months for the standard care arm. These findings, alongside positive results from the ASCENT-03 study reported last month, substantially strengthen Trodelvy's potential as a backbone therapy across all patients in first-line mTNBC, an area with high unmet medical need. This progress is critical for Gilead's strategy to expand its oncology franchise, particularly as its Cell Therapy division (Yescarta and Tecartus) faces anticipated competitive pressures in 2025. The prospective launch of Trodelvy in this expanded indication by 2026, along with anito-cel, is anticipated to fortify Gilead's oncology business significantly. While overall survival (OS) data from the ASCENT-04 study are not yet mature, initial trends are encouraging, and ongoing monitoring of OS will be a key determinant of future impact. The company's stock has appreciated 20% year-to-date, markedly outperforming the industry's 3.1% decline, reflecting investor confidence, and the safety profile of the Trodelvy-Keytruda combination was found to be consistent with the known profiles of each drug.

Key Decisions for Investors

• Investors should evaluate the enhanced commercial prospects for Trodelvy in the first-line mTNBC setting, as the reported 35% risk reduction in disease progression and improved PFS could be a substantial driver for Gilead's oncology revenue growth.
• It is crucial to monitor the forthcoming mature overall survival (OS) data from the ASCENT-04 trial; confirmation of a significant OS benefit would further de-risk Trodelvy's market positioning and could unlock additional shareholder value.
• Consider the positive Trodelvy developments as a significant factor that could mitigate the impact of competitive headwinds anticipated in Gilead's Cell Therapy franchise, thereby assessing the evolving risk-reward profile of the company's diversified oncology portfolio.
• While the clinical data for Trodelvy are strong, investors should note Gilead's 20% year-to-date stock increase and its current Zacks Rank #3 (Hold), suggesting a balanced consideration of the positive news against current valuation and potential market entry points.